Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: F. Jay Abella, III who wrote (3397)	4/17/1998 9:13:00 AM
From: clochard	Read Replies (2) \| Respond to of 7041

One can only feel suspicious about Dauntless' unwavering support of Zonagen. I consider such a person an "insider" because he is biased in some way. I suppose I am biased too, with my small short position, but at least I don't try to pull the wool over everyone's eyes. Zonagen is not a good investment by any standard that I am familiar with. A gamble maybe, but there are a lot better gambles, such as AMLN, FONR, etc.

To: F. Jay Abella, III who wrote (3397)	4/17/1998 9:14:00 AM
From: Anaxagoras	Respond to of 7041

<<Stock to be sold, transactions to be made.>> Jay, that's fine, no one but a neophyte doubts that even the most respectable houses aren't interested in rounding up a little investment banking whenever they can- I bet I can pull up just as many examples of this as you can. However, that wasn't my question, so it's irrelevant.... In this case, it doesn't make a lot of sense unless you think the company is planning on selling some stock soon in the next year or so (otherwise why not just issue "Strong Buys" on anything that moves?), but you suggested this scenario by your reference to the possible filing of an S-3. Now, of course, it's always possible, but I always prefer to consider the probable. Zonagen is in a very strong cash position right now and will be for some time it looks like, so I ask you again to tell me a story about what kind of stock Oppie would be expecting to sell for Zonagen in the next year? I don't see that as plausible, but come on, try again and make something up. Anaxagoras

To: F. Jay Abella, III who wrote (3397)	4/17/1998 10:03:00 AM
From: Dauntless	Read Replies (3) \| Respond to of 7041

Jay - Another pathetic post!! <<<Tell me what you think about this story....>>> OK - here's what I think... Edgar shows the following for Zonagen (full year ending 12/31/97)& Pharmaprint (6 months ending 9/30/97) (sorry about the format) Zonagen Cash in bank - $ 73,762K Net Income - (13,173) Net Cash Flow - (8,255) Pharmaprint Cash in bank - $ 3,281K Net Income - (8,204) Net Cash Flow - (4,829) I think this story has ABSOLUTELY NOTHING in common with Zonagen. With another with another $47 Million in milestone payments already committed by SGP, Zona has several YEARS of cash available. By 12/31 Pharmaprint was probably running on fumes - so they raised money. What the hell does this have in common with Zonagen today? Just explain why a cash rich company like Zonagen would be planning another offering? No, just another cheap shot. <<<I will inundate you with countless other examples of this phenomenon if you like. We'll start with Connectix and Dillon Read.>>> Connectix is a privately held corporation with no financial info publicly available. Please don't innundate me with similar examples. Here's what you need to provide me with - a development stage biotech firm with its first compound through clinical trials, with a major pharma partner that is filing the NDA, with milestone payments already received and others coming, with YEARS of cash in the bank, with a new buy recommendation from a major brokerage/investent banking firm - THEN that brokerage firm participating in a financing round shortly after issuing the rec. Short of that - get a life.